Previous 10 | Next 10 |
Sol-Gel Technologies Ltd. (SLGL) is expected to report $-0.23 for Q3 2023
2023-10-06 13:29:08 ET Gainers: Falcon's Beyond Global (FBYD) +145% . American Oncology Network ( AONC ) +53% . Akso Health Group ( AHG ) +23% . Vigil Neuroscience ( VIGL ) +20% . NuScale Power Corporation ( SMR )...
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and...
2023-08-10 12:22:30 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q2 GAAP EPS of -$0.24 beats by $0.02 . As of June 30, 2023, Sol-Gel had $29.1 million in cash, cash equivalents and deposits, and $17.9 million in marketable securities for a total balance of $...
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will provide up to $11 million in upfront payments and regulatory and sales milestones for...
2023-06-06 12:42:07 ET Israel's Sol-Gel ( NASDAQ: SLGL ) has signed an exclusive licensing deal with Searchlight Pharma for the Canadian commercialization rights to its dermatology products Twyneo and Eposolay. Sol-Gel said it will receive up to $11M in upfront and milestone...
Sol-Gel to receive up to $11 million in upfront payment s and regulatory and sales milestone s for both drugs, combined, plus additional royalties ranging from low double-digits to high - teens Non -di lutive capital stre...
2023-05-12 07:31:54 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q1 GAAP EPS of -$0.41. Revenue of $0.76M. As of March 31, 2023, Sol-Gel had $20.3 million in cash, cash equivalents and deposits, and $18.4 million in marketable securities for a total balance ...
Positive trends continue for TWYNEO ® and EPSOLAY ® with recurrent prescriber base s at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) fo...
2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% . Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Gaucho Group Holdings Inc. (VINO) is expected to report for Q1 2024 Tosoh Corporation (TOSCF) is expected to report for Q4 2024 Adidas AG ADR - Level I (ADDYY) is expected to report $0.69 for Q1 2024 MicroCloud Hologram Inc. (HOLO) is expected to report for Q1 2024 Universal Enter...
NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...